Tag: adjuvant-therapy

Oct 05, 2026

• cancer
• vaccine
• mRNA
• melanoma
• adjuvant-therapy
• keytruda
• moderna
• merck
• mRNA-vaccine
• neoantigen
• phase-3-trial

Oct 04, 2026

• oncology
• immunotherapy
• mRNA-vaccine
• melanoma
• adjuvant-therapy
• keytruda
• moderna
• merck
• immune-checkpoint-inhibitor
• pembrolizumab

Oct 04, 2026

• mrna-vaccine
• cancer-immunotherapy
• personalized-medicine
• neoantigen
• moderna
• merck
• melanoma
• adjuvant-therapy

Oct 04, 2026

• oncology
• immunotherapy
• mRNA-vaccine
• melanoma
• pembrolizumab
• keytruda
• moderna
• merck
• adjuvant-therapy
• pd-1-inhibitor

Oct 04, 2026

• personalized-medicine
• oncology
• mRNA-vaccine
• melanoma
• adjuvant-therapy
• immuno-oncology
• precision-medicine
• genomic-profiling
• targeted-therapy
• neoantigen

Oct 04, 2026

• phase-3-trial
• clinical-trials
• moderna
• merck
• mrna-vaccine
• melanoma
• adjuvant-therapy
• regulatory-approval

Oct 04, 2026

• resected-melanoma
• adjuvant-therapy
• mrna-vaccine
• moderna
• merck
• keytruda
• pembrolizumab
• intismeran-autogene

Oct 03, 2026

• oncology
• immunotherapy
• mRNA-vaccine
• melanoma
• adjuvant-therapy
• keytruda
• moderna
• merck
• personalized-medicine

Sep 26, 2026

• biotech
• oncology
• mRNA
• vaccine
• melanoma
• adjuvant-therapy
• mRNA-therapeutics
• personalized-cancer-vaccine
• resected-melanoma
• merck-partnership

Sep 26, 2026

• mrna-vaccine
• melanoma
• moderna
• merck
• keytruda
• adjuvant-therapy
• phase-3-trial
• intismeran-autogene